The development of macular atrophy leading to RPE atrophy may be related to the frequency with which pan-VEGF-A blockade treatments are administered.[38,39] This could be a serious issue in maintaining good vision in patients with exudative AMD treated with anti-VEGF agents, since follow-up loss was very important in this study, likely due to the duration of the follow-up and comorbidities of patients. This evidence concerns the gene VEGFA and age-related macular degeneration.